inclusion criteria: 1. men or non-pregnant female aged 18 to 65 years hospitalized with moderate covid-19 infection: body temperature \> 37.5 °c; respiratory rate \> 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (ct) changes (ct1- ct2); pulse oximetry levels spo2\< 95%. 2. able to give informed consent and attend all study visits 3. positive pcr-test for covid-19 ≤72 hours prior to randomization 4. the patient's ability to inhale the experimental drug 5. participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month key

inclusion criteria: 1. men or non-pregnant female aged 18 to 65 years hospitalized with moderate covid-19 infection: body temperature \> 37.5 °c; respiratory rate \> 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (ct) changes (ct1- ct2); pulse oximetry levels spo2\< 95%. 2. able to give informed consent and attend all study visits 3. positive pcr-test for covid-19 ≤72 hours prior to randomization 4. the patient's ability to inhale the experimental drug 5. participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month key

inclusion criteria: men or non-pregnant female aged 18 to 65 years hospitalized with moderate covid-19 infection: body temperature > 37.5 °c; respiratory rate > 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (ct) changes (ct1- ct2); pulse oximetry levels spo2< 95%. able to give informed consent and attend all study visits positive pcr-test for covid-19 ≤72 hours prior to randomization the patient's ability to inhale the experimental drug participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month key

inclusion criteria: men or non-pregnant female aged 18 to 65 years hospitalized with moderate covid-19 infection: body temperature > 37.5 °c; respiratory rate > 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (ct) changes (ct1- ct2); pulse oximetry levels spo2< 95%. able to give informed consent and attend all study visits positive pcr-test for covid-19 ≤72 hours prior to randomization the patient's ability to inhale the experimental drug participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month key